Background The infection by coronavirus disease 2019 (COVID‐19) has been associated with multiple cutaneous manifestations, although characterization of them in Hispanic patients with darker skin phototypes is lacking. The objective of this study is to characterize the clinical dermatological manifestations associated with COVID‐19 infection in cases with few or without general symptoms in patients from Latin America. Methods Cross‐sectional study using a questionnaire that was made for health professionals (physicians with a specialty in dermatology) to investigate dermatological lesions associated with COVID‐19 infection in patients from 25 countries of Latin America. The survey was active from June 9 to July 30, 2020. Results In this study, information was collected from a total of 347 patients. We found a female gender predominance: 179/347 (51.6%). The mean age at presentation was 40.87 years. The most frequent dermatological manifestations were maculopapular rash and urticarial lesions, followed by papulovesicular lesions, vesicular lesions, chilblain‐like lesions, papular lesions, ecchymosis, petechial purpura, pityriasis rosea‐like lesions, pruritus, palmoplantar dysesthesias, transient livedo, acral necrosis, palpable purpura, livedo racemosa, and retiform purpura. As far as we know, there are no previous reports of pruritus and palmoplantar dysesthesias. Conclusions This registry emphasizes skin manifestations as an important criterion for establishing the diagnosis of COVID‐19 infection in Latin American countries. This information will be useful for the early identification of suspected cases by health professionals (dermatologists and nondermatologists) and will allow contact tracing to mitigate the impact on health systems at different levels.

Fortalecer la protección a la salud tanto de los pacientes como del especialista y de su personal de apoyo, ya que la pandemia de COVID-19 impone modificaciones a la práctica médica. Material y métodos: Un grupo de expertos dermatólogos latinoamericanos emite recomendaciones para la práctica dermatológica segura, dentro del escenario de la pandemia de COVID-19, en lo que respecta a información básica, capacitación y supervisión en protección personal, antecedentes del paciente, manejo de expedientes, mejoramiento en las áreas no médicas relacionadas con el control del consultorio, junto con la vigilancia de probables casos de contagio en los pacientes. Resultados: Las recomendaciones abarcan las actividades antes, durante y después de la consulta. Se tratan aspectos como el arreglo del consultorio, el control del flujo de trabajo, los procedimientos de asepsia, el tiempo y la atención de las áreas dermatológicas o el uso de los medios digitales para la atención. Conclusiones: El diseño de protocolos adecuados depende de que los especialistas comprendan las características del comportamiento de casos de COVID-19 en su localidad y mantengan contacto con autoridades de salud y centros de atención a síntomas para determinar los tiempos de cierre y reapertura del consultorio.

Objetivo. Proporcionar recomendaciones para la detección temprana de pacientes con alto riesgo de desarrollar cáncer de pulmón (CP) en el primer nivel de atención y su referencia oportuna. Material y métodos. Se realizó una búsqueda detallada de la evidencia científica disponible para responder las preguntas de investigación clínica y se utilizó el Panel Delphi modificado para lograr un consenso entre expertos. Resultados. Se generaron 14 recomendaciones siguiendo los estándares de una GPC. Conclusión. El CP representa un problema de salud pública en México; por ello, esta guía establece recomendaciones que apoyan la toma de decisiones sobre la detección precoz y la referencia de pacientes con sospecha de CP en el primer nivel de atención.

Las tecnologías de información y comunicación (TIC), incluida la teledermatología, han cobrado mayor relevancia durante la actual pandemia por COVID-19, y se ha convertido en un instrumento estratégico para la atención a la salud debido a las restricciones que afectan a la atención presencial.

Introduction. Osteoarthrosis (OA) is the most common rheumatic disease and often results in disability. Its treatment must be comprehensive and consider several aspects. However, the chronic use of anti-inflammatory drugs is associated with severe gastrointestinal, cardiovascular, hematological, and renal adverse reactions. Medicinal plants have been used for centuries in the management of this disease. Objective. This study aimed to carry out a systematic review of the published evidence of 13 plants whose use in OA has been reported. Material and Methods. The search strategy included the following criteria: documents written in English and Spanish, full texts, studies in humans, clinical guidelines, systematic reviews, meta-analysis, randomized clinical studies, observational /epidemiological/ economic studies, reviews, consensus. Particular emphasis was placed on the pharmacological mechanism of action that could justify their use and support the clinical efficacy. The evidence obtained was selected through work questions and level of evidence. Results. Seven hundred and thirty-four articles were found; 346 out of them were chosen to be analyzed. Pro-inflammatory cytokines inhibition, reduction in TNF-α and NF-κB signaling, decrease in osteoclastogenesis, increase in the osteoclasts differentiation, decrease in cyclooxygenase 2 activity, and prostaglandins synthesis are among the mechanisms of action of the studied plants. Conclusions. The several plants reviewed have mechanisms of action that support their use in treating OA and have varying degrees of demonstrated efficacy.